Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014
Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014
Summary
...
clinical Stage Products 13
early Stage Products 14
hypogonadotropic Hypogonadism - Products Under Development By Companies...
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchm...
Upcoming SlideShare
Loading in …5
×

Latest Report: Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014

243 views

Published on

Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014 @ http://www.researchmoz.us/hypogonadotropic-hypogonadism-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Healthcare, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
243
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Latest Report: Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014

  1. 1. Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014 Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014 Summary Global Markets Directs, Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014, provides an overview of the Hypogonadotropic Hypogonadisms therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hypogonadotropic Hypogonadism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hypogonadotropic Hypogonadism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hypogonadotropic Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hypogonadotropic Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypogonadotropic Hypogonadism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypogonadotropic Hypogonadism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 4 introduction 5 global Markets Direct Report Coverage 5 hypogonadotropic Hypogonadism Overview 6 therapeutics Development 7 pipeline Products For Hypogonadotropic Hypogonadism - Overview 7 pipeline Products For Hypogonadotropic Hypogonadism - Comparative Analysis 8 hypogonadotropic Hypogonadism - Therapeutics Under Development By Companies 9 hypogonadotropic Hypogonadism - Therapeutics Under Investigation By Universities/institutes 11 hypogonadotropic Hypogonadism - Pipeline Products Glance 12 late Stage Products 12 Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014
  2. 2. clinical Stage Products 13 early Stage Products 14 hypogonadotropic Hypogonadism - Products Under Development By Companies 15 hypogonadotropic Hypogonadism - Products Under Investigation By Universities/institutes 16 hypogonadotropic Hypogonadism - Companies Involved In Therapeutics Development 17 merck & Co., Inc. 17 novartis Ag 18 repros Therapeutics Inc. 19 alphamab Co., Ltd 20 hypogonadotropic Hypogonadism - Therapeutics Assessment 21 assessment By Monotherapy Products 21 assessment By Combination Products 22 assessment By Target 23 assessment By Mechanism Of Action 26 assessment By Route Of Administration 29 assessment By Molecule Type 31 drug Profiles 33 enclomiphene - Drug Profile 33 product Description 33 mechanism Of Action 33 r&d Progress 33 corifollitropin Alfa - Drug Profile 35 product Description 35 mechanism Of Action 35 r&d Progress 35 bgs-649 - Drug Profile 37 product Description 37 mechanism Of Action 37 r&d Progress 37 kisspeptin 112-121 + [gonadorelin] - Drug Profile 38 product Description 38 mechanism Of Action 38 r&d Progress 38 follitropin Alfa Biosimilar - Drug Profile 39 product Description 39 mechanism Of Action 39 r&d Progress 39 hypogonadotropic Hypogonadism - Recent Pipeline Updates 40 hypogonadotropic Hypogonadism - Product Development Milestones 50 featured News & Press Releases 50 jan 08, 2014: Repros Initiates Two Head To Head Studies Of Androxal Versus The Leading Topical Testosterone Gel 50 dec 04, 2013: Auxilium Pharmaceuticals Announces Court Grants Upsher-smith Laboratories Motion For Summary Judgment 50 nov 25, 2013: Fda Schedules Face To Face Meeting With Repros To Discuss Androxal Efficacy 51 nov 25, 2013: Repros To Present Data On The Benefits Of Testosterone Restoration With Androxal Compared To T Replacement With Gels At 9th Men's Health World Congress 51 oct 22, 2013: Repros Receives Fda Guidance For Androxal Clinical Program 52 oct 07, 2013: Repros Announces Three Studies Accepted For Presentation At The Annual Meeting Of The Sexual Medicine Society Of North America 53 sep 18, 2013: Repros Provides Additional Information Confirming Success For Study Za-302 53 aug 05, 2013: Repros Seeks To Affirm Its Intellectual Property Rights In Androxal 54 jul 09, 2013: Repros Announces Formation Of Androxal Clinical And Commercial Advisory Board 54 may 02, 2013: Repros Reports Second Pivotal Androxal Study Fully Enrolled Ahead Of Schedule 56 appendix 57 methodology 57 coverage 57 secondary Research 57 primary Research 57 expert Panel Validation 57 contact Us 58 disclaimer 58 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014
  3. 3. Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014

×